Journal Guide
Journal of Clinical Investigation Impact Factor 13.6: Publishing Guide
The premier translational medicine journal: where disease mechanisms meet clinical relevance
13.6
Impact Factor (2024)
~8-10%
Acceptance Rate
2-4 weeks to first decision
Time to First Decision
What J. Clin. Investigation Publishes
JCI publishes research that uncovers mechanisms of disease and points toward better treatments. It lives in the space between Cell (pure mechanism) and NEJM (pure clinical outcomes). If you have discovered something fundamental about how a disease works, and that discovery has real implications for patients, JCI is the journal. Pure basic science without disease relevance goes to Cell or Nature. Clinical trials without mechanistic insight go to NEJM or Lancet. JCI wants the connection between the two.
- Mechanistic studies of disease biology using preclinical models and human-derived materials
- Phase I/II clinical studies with translational insights
- Discovery of therapeutic targets with validation in disease models
- Biomarker identification and clinical validation
- Immunology, metabolism, oncology, neuroscience, and vascular biology (among many specialties)
- Public health research informing disease pathogenesis, therapeutics, or prevention
Editor Insight
“JCI occupies a unique position in biomedical publishing. It is the journal for physician-scientists: people who think about molecules on Monday and see patients on Tuesday. If your research sits purely on one side (bench or bedside), other journals serve you better. But if your work connects a disease mechanism to a clinical question, or takes a clinical observation back to the lab to explain it, JCI is where that story belongs. The ASCI has been championing this type of science since 1908, and JCI is its flagship.”
What J. Clin. Investigation Editors Look For
Mechanistic depth with disease relevance
JCI wants to know HOW disease works at a molecular or cellular level. But unlike Cell, every mechanistic finding needs to connect back to human disease. 'We found a new pathway' is not enough. 'We found a pathway that explains why patients get worse' is JCI territory.
Human data or clear human applicability
Mouse-only papers can still get in, but they need strong human relevance. Patient samples, human genetics data, or human cell models significantly strengthen a submission. The best JCI papers go from bench to bedside (or at least to the bedside door).
Broad appeal across medical specialties
JCI readers are physician-scientists across all of medicine. A paper on kidney disease needs to interest an immunologist. Work on cancer metabolism should intrigue a cardiologist. If only subspecialists in your exact area would read it, a specialty journal may be better.
Novel therapeutic or diagnostic implications
JCI loves papers that end with 'and this suggests a new way to treat or diagnose the disease.' You do not need Phase 3 trial data (that is for NEJM), but you need to show that your discovery has therapeutic potential.
Rigorous experimental design across model systems
Multiple complementary approaches strengthen JCI papers. In vitro plus in vivo. Genetic plus pharmacological. Loss of function plus gain of function. The editorial board is composed of active researchers who know what proper controls look like.
Sex as a biological variable
JCI requires authors to address sex as a biological variable in their study design. If you only used one sex, you need to justify it and discuss whether findings apply more broadly. This is not optional.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past J. Clin. Investigation's editorial review:
Submitting pure basic science without disease connection
JCI is not Cell or Nature. If your paper describes elegant biology but never connects to a disease, the editors will redirect you. Every JCI paper should reference a disease in the title.
Submitting clinical trial results without mechanistic insight
If your paper shows a drug works but does not explain why, NEJM or Lancet is the better home. JCI wants the 'how it works' alongside the 'that it works.'
Failing to connect preclinical findings to human disease
A mouse study that never mentions human relevance will struggle. At minimum, include human tissue validation, patient genetics, or a clear translational rationale.
Ignoring the structured requirements
JCI has specific formatting rules: 15-word title limit, no colons in titles, mandatory sex-as-biological-variable paragraph, study approval section, data availability statement. Missing these signals that you did not read the guidelines.
Overloading the manuscript beyond word limits
The recommended length is 9,000 words with a hard cap at 12,000 (everything included). Bloated manuscripts suggest unfocused thinking. Be concise.
Using bar graphs instead of dot plots
JCI requires dot plots or box-and-whisker plots showing data distribution. Bar graphs hiding individual data points will get flagged immediately.
Does your manuscript avoid these patterns?
The quick diagnostic reads your full manuscript against J. Clin. Investigation's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from J. Clin. Investigation Authors
JCI is run by active researchers, not professional editors alone
The editorial board is composed of physician-scientists at Northwestern University who meet weekly to review manuscripts. They are working researchers in your field. This means they read papers like scientists, not administrators. They can spot weak controls and thin data from experience.
Use the Dual-Journal Submission option strategically
JCI offers a dual submission track where your paper is evaluated for both JCI and JCI Insight simultaneously. If JCI passes, it automatically routes to JCI Insight with the same reviews. This saves months compared to sequential submissions.
You can transfer reviews from other journals
When submitting to JCI, you can include reviews from a previous journal submission along with a point-by-point response. The editors will consider these, though they may still send to additional reviewers.
Presubmission inquiries are available but not required
You can email the editors with your abstract and a pitch for why the work fits JCI. This is informal guidance, not a substitute for peer review, but it can save you time if your topic is clearly outside scope.
The title must reference the disease studied
JCI explicitly requires that titles refer to the relevant disease or disease model. Titles that only describe a molecular finding without naming the disease will be sent back for revision before review even starts.
Clinical Research and Public Health is a distinct category
JCI created a dedicated track for human-participant research, from small patient studies to large epidemiological analyses. This track requires structured abstracts, ICMJE forms, and appropriate reporting checklists. It is not just for clinical trials.
Graphical abstracts are optional but increasingly expected
While not mandatory for first submission, a strong graphical abstract improves visibility. JCI articles with graphical abstracts get more engagement on social media and in browsing.
JCI is fully open access with real costs
Since 2022, JCI is Gold Open Access. The publication fee is $5,800 (slightly less for ASCI members). Budget for this. Fee discounts are available on a case-by-case basis, but they are not automatic.
The J. Clin. Investigation Submission Process
Presubmission inquiry (optional)
Response within 1-2 weeksEmail the editors with your abstract and a brief statement on why the work fits JCI. They will provide informal guidance on suitability.
Full submission
Acknowledgment within daysComplete manuscript with cover letter, supporting data values file (XLS), and optional graphical abstract. Choose between Research, Clinical Research and Public Health, or Research Letter categories. Optionally select Dual-Journal Submission for JCI + JCI Insight consideration.
Editorial screening
1-2 weeks; ~25-30% desk rejectionScience Editors assign the paper to an Associate Editor. The full editorial board reviews weekly. Papers may be declined without external review if judged to lack sufficient novelty or scope for JCI.
External peer review
3-5 weeks2-3 expert reviewers assess scientific rigor, novelty, and relevance to disease biology. Reviewers assign priority based on content, originality, quality, and interest to readers.
Decision
2-4 weeks total to first decisionAccept, reject, or revise. Revision requests may include additional experiments, especially human validation data. The full board discusses each decision.
Revision and resubmission
Typically 2-4 months for revisionRevised manuscripts undergo re-evaluation by the Associate Editor and potentially re-review. Point-by-point responses to all reviewer comments are required.
J. Clin. Investigation by the Numbers
| 2024 Impact Factor(Clarivate JCR) | 13.6 |
| 5-Year Impact Factor | 14.4 |
| H-index(Scopus) | 558 |
| Acceptance rate(Estimated; not officially published) | ~8-10% |
| Desk rejection rate | ~25-30% |
| Publication frequency | Semi-monthly (24 issues/year) |
| Open access | Gold OA since 2022 (CC BY 4.0) |
| Publication fee($5,600 for ASCI members) | $5,800 |
Before you submit
J. Clin. Investigation accepts a small fraction of submissions. Make your attempt count.
The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to J. Clin. Investigation. ~30 minutes.
Article Types
Research
9,000-12,000 wordsFull mechanistic studies of disease biology using preclinical models and human materials. The core article type.
Clinical Research and Public Health
9,000-12,000 wordsHuman-participant studies: clinical trials, observational analyses, epidemiology, health disparities, outcomes research. Requires structured abstract and reporting checklists.
Research Letter
1,200 words, 1 figure or tableFocused reports of a single preclinical or clinical finding of exceptional interest. One display item only.
Letter to the Editor
850 words, 1 figure or tableComments on recently published JCI articles. Must be submitted within 1 month of the original article's publication.
Landmark J. Clin. Investigation Papers
Papers that defined fields and changed science:
- Fractionation of lipoproteins in human serum, defining LDL and HDL (Havel et al., 1955)
- Goldstein and Brown's work on familial hypercholesterolemia inheritance, leading to statin development (1973)
- Discovery of macrophage accumulation in adipose tissue linking obesity to inflammation (Weisberg et al., 2003)
- Elevation of natriuretic peptides in heart failure, now a standard clinical biomarker (1986)
- GLP-1 incretin pathway studies that laid the foundation for modern diabetes and obesity drugs
Preparing a J. Clin. Investigation Submission?
Get pre-submission feedback from reviewers who've published in J. Clin. Investigation and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? Human review from $1,000
Primary Fields
Ready to submit to J. Clin. Investigation?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what J. Clin. Investigation editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to J. Clin. Investigation. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to J. Clin. Investigation reviewers.
Need field-expert depth? Human review from $1,000